Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaccine and antibody combo stop ebola after exposure?

NCT ID NCT05202288

Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether giving the Ervebo Ebola vaccine together with the antibody drug Inmazeb still works to protect people who may have been exposed to Ebola. The vaccine alone takes time to work, while antibodies act fast but might interfere with the vaccine. Researchers will give 132 healthy adults different combinations and timings to find the best approach for post-exposure protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ervebo (Ebola vaccine) and Inmazeb (antibody drug)
What this could lead to
If successful, this could show how to use both a vaccine and antibody together for better short- and long-term protection after Ebola exposure.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. The antibody might block the vaccine's effect, and results may not apply to real outbreaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Available for the duration of the protocol follow-up; * Consent to participate ; * Agreed not to participate in another clinical research study until the end of the trial follow-up. Exclusion Criteria: * Prior history of EVD (self-reported); * Previous vaccination with r-VSV-ZEBOV or any other Ebola vaccine (self-reported); * Previous administration of Ebola antibody; * HIV-1 and/or 2 positive serology; * Pregnant women (positive pregnancy test); * Breastfeeding women; * To the opinion of the investigator, any clinically significant acute/chronic condition that would limit the participant\'s ability to meet the requirements of the study protocol; * Taking Immunosuppressive therapy; * Participation in another clinical research study within the last 30 days; * Allergy to any component of the vaccine or Mabs; * Person deprived of freedom by a judicial or administrative decision; * Any other reason that, at the investigator\'s discretion, would compromise the participant\'s safety and cooperation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ebola virus disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.